MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Income Statement
NASDAQ:MDGL - Nasdaq - US5588681057 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 317.38M | 180.13M | 0.00 | 0.00 | 0.00 | |||
| Cost Of Goods | 10.75M | 6.23M | N/A | N/A | N/A | |||
| Gross Profit | 306.64M | 173.90M | N/A | N/A | N/A | |||
| Operating Expenses | 731.78M | 671.77M | 380.50M | 293.60M | 242.50M | |||
| Research and Development | 209.65M | 236.72M | 272.35M | 245.40M | 205.20M | |||
| Selling, General, and Administrative Expenses | 522.13M | 435.06M | 108.15M | 48.10M | 37.30M | |||
| Operating Income | -425.15M | -497.88M | -380.50M | -293.60M | -242.50M | |||
| Interest Income/Expense | 33.56M | 31.98M | 6.87M | -1.80M | 400.00K | |||
| Other Income/Expense | N/A | N/A | 0.00 | 0.00 | 300.00K | |||
| Income Before Taxes | -391.59M | -465.89M | -373.63M | -295.40M | -241.80M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -391.59M | -465.89M | -373.63M | -295.40M | -241.80M | |||
| EBITDA | -423.84M | -496.78M | -379.97M | -293.13M | -242.09M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -18.04 | -21.90 | -19.99 | -17.27 | -14.65 | |||
| Non GAAP EPS | -18.05 | -22.11 | -19.94 | -17.23 | -14.61 | |||
| Statistics | ||||||||
| Gross Profit Margin | 96.61% | 96.54% | N/A | N/A | N/A | |||
| Profit Margin | -123.38% | -258.64% | N/A | N/A | N/A | |||
| Operating Profit Margin | -133.95% | -276.39% | N/A | N/A | N/A | |||
All data in USD